Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Galmed Pharmaceuticals Ltd
GLMDCurrent price
3.02 USD
-0.24 USD (-7.36%)
Last closed
3.42 USD
Company
www.galmedpharma.com
ISIN
IL0011313900
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
2 175 685 USD
Yield for 12 month
-68.81 %
1Y
3Y
5Y
10Y
15Y
GLMD
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. Address: 16 Abba Hillel Road, Ramat Gan, Israel, 5250608
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
12 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-31 000 USD
Last Year
-35 000 USD
Current Quarter
–
Last Quarter
-9 000 USD
Key Figures GLMD
1 year
3 years
5 years
10 years
EBITDA
-6 145 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-29.31 %
PEG Ratio
–
Return On Equity TTM
-52.67 %
Wall Street Target Price
12 USD
Revenue TTM
–
Book Value
22.24 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-10.44 USD
Diluted Eps TTM
-10.44 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics GLMD
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History GLMD
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:12
Payout Ratio
–
Last Split Date
30.08.2024
Dividend Date
–
Stock Valuation GLMD
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
0.3212
Price Book MRQ
0.1846
Financials GLMD
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators GLMD
For 52 weeks
2.86 USD
10.8 USD
50 Day MA
3.61 USD
Shares Short Prior Month
10 246
200 Day MA
4.28 USD
Short Ratio
0.36
Shares Short
12 057
Short Percent
0.2 %
BeatStart